A5013551167- Epigenetics and DNA Methylation
- Bladder and Urothelial Cancer Treatments
- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Renal cell carcinoma treatment
- Organ Donation and Transplantation
- Advanced Breast Cancer Therapies
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- FOXO transcription factor regulation
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Urinary and Genital Oncology Studies
- Multiple and Secondary Primary Cancers
- Viral-associated cancers and disorders
- Venous Thromboembolism Diagnosis and Management
- Prostate Cancer Diagnosis and Treatment
- Cardiac tumors and thrombi
- Cancer-related gene regulation
- Blood groups and transfusion
- Cytomegalovirus and herpesvirus research
- Lung Cancer Treatments and Mutations
- Tissue Engineering and Regenerative Medicine
- Organ and Tissue Transplantation Research
- Immune responses and vaccinations
Hospital Universitario 12 De Octubre
2006-2023
Research Institute Hospital 12 de Octubre
2012-2022
Marche Polytechnic University
2022
Ospedale Monaldi
2021
Centro de Investigación Biomédica en Red de Cáncer
2017-2018
Hospital Clínico San Carlos
2010
Central University Hospital of Asturias
2010
Hospital Universitario Virgen del Rocío
2010
Purpose: Bladder cancer is a current clinical and social problem. At diagnosis, most patients present with nonmuscle-invasive tumors, characterized by high recurrence rate, which could progress to muscle-invasive disease metastasis. Bone morphogenetic protein (BMP)-dependent signaling arising from stromal bladder tissue mediates urothelial homeostasis promoting cell differentiation. However, the possible role of BMP ligands in still unclear.Experimental Design: Tumor normal 68 were...
7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation inhibitor with single-agent antitumor activity and has shown additive effects when added to chemotherapy in preclinical models. TALENT was placebo-controlled study patients (pts) previously untreated advanced NSCLC receive at 150mg/d or placebo (PBO) 6 cycles of gemcitabine cisplatin (GC) followed by monotherapy. The primary endpoint duration survival secondary efficacy endpoints of: time progression,...
LBA4518 Background: Approximately half of patients with resected invasive bladder cancer will die within the first three years after surgery due to disease relapse, most recurrences being systemic. We have studied in a randomized phase III trial role 4 courses PGC triplet as compared observation this clinical setting. Methods: Eligibility criteria included: (1) high-risk muscle carcinoma (pT3-4 and/or pN+), (2) ECOG PS 0-1, (3) adequate renal function (CrCl > 50 ml/min), (4) ≤ 8 weeks...
Bladder cancer (BC) is one of the most common cancers in western world and ranks as expensive to manage, due need for cystoscopic examination. BC shows frequent changes DNA methylation, several studies have shown potential utility urinary biomarkers by detecting epigenetic alterations voided urine. The aim this study develop a targeted bisulfite next-generation sequencing assay diagnose from urine with high sensitivity specificity. We defined 150 CpG loci biomarker panel cohort 86...
Bladder cancer is a highly prevalent human disease in which retinoblastoma (Rb) pathway inactivation and epigenetic alterations are common events. However, the connection between these two processes still poorly understood. Here, we show that vivo of all Rb family genes mouse urothelium sufficient to initiate bladder development. The characterization tumors revealed multiple molecular features cancer, including activation E2F transcription factor subsequent Ezh2 expression several signaling...
Long non-coding RNAs (lncRNAs) have been claimed as key molecular players in gene expression regulation, being involved diverse epigenetic processes. They are aberrantly expressed various tumors, but their exact role bladder cancer is still obscure. We recently found a major of the Polycomb repression complex recurrence non-muscle-invasive cancer. Here, we report xpression Polycomb-related lncRNAs:antisense noncoding RNA INK4 locus (ANRIL) and HOX antisense intergenic (HOTAIR) these...
Bladder cancer (BC) is the fifth most common in world, being non-muscle invasive tumors (NMIBC) frequent. NMIBC shows a very high frequency of recurrence and, certain cases, tumor progression. The phosphatidylinositol 3-kinase (PI3K) pathway, which controls cell growth, tumorigenesis, invasion and drug response, frequently activated numerous human cancers, including BC, part through alterations PIK3CA gene. However, significance gene with respect to clinicopathological characteristics,...
Uncontrolled donation after circulatory death (uDCD) increases organ availability for kidney transplant (KT) with short-term outcomes similar to those obtained from brain (DBD) donors. However, heterogeneous results in the long term have been reported. We compared 10-year between 237 KT recipients uDCD donors maintained by normothermic extracorporeal membrane oxygenation (nECMO) and patients undergoing standard criteria DBD during same period at our institution. further analyzed risk factors...
Abstract Purpose: Bladder cancer is a clinical and social problem due to its high incidence recurrence rates. It frequently appears in elderly patients showing other medical comorbidities that hamper the use of standard chemotherapy. We evaluated activity CDK4/6 inhibitor as new therapy for unfit cisplatin (CDDP). Experimental Design: cell lines were tested vitro sensitivity inhibition. A novel metastatic bladder mouse model was developed used test vivo activity. Results: Cell sensitive...
The HeartLogic algorithm combines multiple implantable cardioverter-defibrillator sensors to identify patients at risk of heart failure (HF) events. We sought evaluate the stratification ability this in clinical practice. also analyzed alert management strategies adopted study group and their association with occurrence HF events.The feature was activated 366 cardiac resynchronization therapy 22 centers. median follow-up 11 months [25th-75th percentile: 6-16]. calculates a daily index...
Bladder cancer (BC) is a highly prevalent disease, ranking fifth in the most common cancers worldwide. Various miRNAs have recently emerged as potential prognostic biomarkers cancer. The miR-200 family, which repressed epithelial-to-mesenchymal transition (EMT), multiple advanced cancers. However, its expression and function BC still poorly understood. Here we show that family displays increased expression, probably due to activation of specific oncogenic signaling pathways, reduced promoter...
Abstract Background In 2005, our center started a donation after cardiac death ( DACD ) program, by which patients who present an irreversible arrest outside hospital are brought to with the purpose of organ donation. We reviewed outcomes program kidney transplants from . Methods conducted retrospective study , and we procedures carried out in institution between J uly 2005 D ecember 2010 descriptively analyzed results obtained for Results One hundred fifty‐two 274 potential donors were...
// Cristina Segovia 1, 2, 3, * , Mónica Martínez-Fernández Marta Dueñas Carolina Rubio 3 Fernando F. López-Calderón 2 Clotilde Costa 4 Saiz-Ladera 5 María Fernández-Grajera 1 José Duarte Huberto García Muñoz 6 Federico de la Rosa Felipe Villacampa Daniel Castellano Jesús M. Paramio Unidad Oncología Molecular, CIEMAT (ed70A), Madrid, Spain Grupo celular y Hospital Universitario 12 Octubre, Centro Investigación Biomédica en Red Cáncer (CIBER ONC), Mixta Roche-CHUS, Santiago Compostela,...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jun 2002Primary Cisplatin, Methotrexate and Vinblastine Chemotherapy With Selective Bladder Preservation for Muscle Invasive Carcinoma the Bladder: Long-Term Followup a Prospective Study F. de la ROSA, R. GARCIA-CARBONERO, J. PASSAS, A. ROSINO, P. LIANES, L. PAZ-ARES ROSAF. ROSA , GARCIA-CARBONEROR. GARCIA-CARBONERO PASSASJ. PASSAS ROSINOA. ROSINO LIANESP. LIANES PAZ-ARESL. View All Author...
TPS598 Background: Intravesical Bacillus Calmette-Guerin (BCG) induction + BCG maintenance after transurethral resection (TURBT) is the current standard of care for patients (pt) with high-risk non-muscle invasive bladder cancer (NMIBC). Recurrence rate at 2 years around 30%, which clearly unsatisfactory. Programmed death ligand 1 (PD-L1) a surface glycoprotein that functions as an inhibitor T-cells and plays crucial role in suppression cellular immune response. Atezolizumab humanized IgG1...
e16590 Background: Intravesical Bacillus Calmette-Guerin (BCG) induction + BCG maintenance after transurethral resection (TURBT) is the current standard of care for patients (pt) with high-risk non-muscle invasive bladder cancer (NMIBC). Recurrence rate at 2 years around 30%, which clearly unsatisfactory. Atezolizumab a humanized IgG1 monoclonal antibody targeting PD-L1 and associated long-term durable remissions in pts metastatic urothelial (Powles T. Lancet. 2018). Pembrolizumab...
Bipolar hemiarthroplasty (BHA) and total hip arthroplasty (THA) are validated treatments for displaced femoral neck fractures (DFNFs). BHA seldomly needs conversion to THA, but the latter has higher dislocation rate in FNFs. Dual Mobility THA offers a reduced eliminates risk of conversion. This study looks differences between DMTHA terms surgical time, blood loss transfusion, rate, mortality, thromboembolic events.All patients were ≥75yo. Recorded data included use anticoagulant/antiplatelet...
395 Background: Renal-cell carcinoma (RCC) accounts for 3% of all cancers and produces over 12,000 deaths every year in the EE.UU. Currently, there is a need to identify stage I/II RCC patients with high risk relapse following nephrectomy, given that these do not receive adjuvant treatment ≈ 25% them relapse. MicroRNAs (miRNAs) are class small noncoding RNAs control gene expression by targeting mRNA playing an important role as regulators during tumorigenesis. Our willing define miRNA...
4620 Background: Sunitinib (SU) is a multi-targeted receptor tyrosine kinase inhibitor treatment that approved for metastatic renal cell carcinoma (mRCC). However, several patients either do not respond to or they experience significant toxicity.Our study aims find genetic markers of toxicity and efficacy using commercially available DNA microarray genotyping system. Methods: 30 with newly diagnosed mRCC, from January 2010 May 2011, were evaluated prospectively at Hospital 12 de Octubre...
We evaluate the efficacy and bladder preservation rate of combined modality therapy consisting deep transurethral resection primary tumor followed by cisplatin, methotrexate vinblastine chemotherapy in patients with muscle invasive transitional cell carcinoma bladder.A total 40 consecutive clinical stage T2-T4 NX M0 cancer were included study treated 3 courses chemotherapy. Chemotherapy consisted 100 mg./m.2 cisplatin intravenously on day 1, 30 days 1 8, 4 8 administered every 21 days....